NR4A1 and cancer: To allow postponement of surgery, 951 patients had ‘bridging’ ET (defined in the protocol as ‘Patient with hormone receptor-positive cancer having ‘bridging’ endocrine therapy due to a potential delay in surgery’), of which the vast majority (708/862, 82%) were postmenopausal (Table 2).